Identification of novel biomarkers in renal cell carcinoma.

IF 3.9 3区医学 Q1 PATHOLOGY

Expert Review of Molecular Diagnostics Pub Date : 2025-06-11 DOI:10.1080/14737159.2025.2518134

Fernanda Fernandes-Pontes, João Lobo, Carmen Jeronimo, Rui Henrique

{"title":"Identification of novel biomarkers in renal cell carcinoma.","authors":"Fernanda Fernandes-Pontes, João Lobo, Carmen Jeronimo, Rui Henrique","doi":"10.1080/14737159.2025.2518134","DOIUrl":null,"url":null,"abstract":"Introduction: Renal Cell Carcinoma (RCC) is a heterogeneous disease, with distinct clinical outcomes for each subtype. Even within subtypes, outcomes differ and there is a need for novel biomarkers enabling risk stratification or predicting response to targeted therapies.Areas covered: Epigenetic alterations, particularly aberrant DNA methylation and microRNAs deregulation, are a biomarker source that might be evaluated in liquid biopsies. Moreover, despite the ground knowledge that RCC comprises different histological entities, most studies still focus on 'RCC' in general and do not consider different subtypes. The most promising microRNAs for ccRCC identification are miR-210-3p, miR-21-3p, and miR-155-5p, which might help accurately subtype RCC, being closer to clinical routine but still lacking validation. Besides, miR-146-a and miR-126-a are promising biomarkers to predict response to immune checkpoint inhibitors.Expert opinion: Substantial developments in molecular diagnostics have been recently made, namely regarding liquid biopsies, despite the lack of biomarkers approved for clinical routine. The inclusion of dedicated Pathologists in biomarker studies remains crucial to truly achieving clinical relevance. Furthermore, combination of artificial intelligence with molecular biomarkers may foster personalized RCC management, with improved precision.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"1-13"},"PeriodicalIF":3.9000,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Molecular Diagnostics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737159.2025.2518134","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Renal Cell Carcinoma (RCC) is a heterogeneous disease, with distinct clinical outcomes for each subtype. Even within subtypes, outcomes differ and there is a need for novel biomarkers enabling risk stratification or predicting response to targeted therapies.

Areas covered: Epigenetic alterations, particularly aberrant DNA methylation and microRNAs deregulation, are a biomarker source that might be evaluated in liquid biopsies. Moreover, despite the ground knowledge that RCC comprises different histological entities, most studies still focus on 'RCC' in general and do not consider different subtypes. The most promising microRNAs for ccRCC identification are miR-210-3p, miR-21-3p, and miR-155-5p, which might help accurately subtype RCC, being closer to clinical routine but still lacking validation. Besides, miR-146-a and miR-126-a are promising biomarkers to predict response to immune checkpoint inhibitors.

Expert opinion: Substantial developments in molecular diagnostics have been recently made, namely regarding liquid biopsies, despite the lack of biomarkers approved for clinical routine. The inclusion of dedicated Pathologists in biomarker studies remains crucial to truly achieving clinical relevance. Furthermore, combination of artificial intelligence with molecular biomarkers may foster personalized RCC management, with improved precision.

查看原文本刊更多论文

肾细胞癌新生物标志物的鉴定。

导读：肾细胞癌（RCC）是一种异质性疾病，每种亚型具有不同的临床结果。即使在亚型中，结果也有所不同，因此需要新的生物标志物来进行风险分层或预测对靶向治疗的反应。涉及领域：表观遗传改变，特别是异常DNA甲基化和microrna解除管制，是可能在液体活检中评估的生物标志物来源。此外，尽管基础知识认为RCC包括不同的组织学实体，但大多数研究仍然集中在一般的“RCC”上，而没有考虑不同的亚型。最有希望用于ccRCC鉴定的microrna是miR-210-3p、miR-21-3p和miR-155-5p，它们可能有助于准确划分RCC亚型，更接近临床常规，但仍缺乏验证。此外，miR-146-a和miR-126-a是预测免疫检查点抑制剂应答的有希望的生物标志物。专家意见：尽管缺乏批准用于临床常规的生物标志物，但分子诊断最近取得了重大进展，即液体活检。在生物标志物研究中纳入专门的病理学家对于真正实现临床相关性仍然至关重要。此外，人工智能与分子生物标志物的结合可以促进个性化的RCC管理，提高精度。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Molecular Diagnostics 医学-病理学

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Expert Review of Molecular Diagnostics (ISSN 1473-7159) publishes expert reviews of the latest advancements in the field of molecular diagnostics including the detection and monitoring of the molecular causes of disease that are being translated into groundbreaking diagnostic and prognostic technologies to be used in the clinical diagnostic setting. Each issue of Expert Review of Molecular Diagnostics contains leading reviews on current and emerging topics relating to molecular diagnostics, subject to a rigorous peer review process; editorials discussing contentious issues in the field; diagnostic profiles featuring independent, expert evaluations of diagnostic tests; meeting reports of recent molecular diagnostics conferences and key paper evaluations featuring assessments of significant, recently published articles from specialists in molecular diagnostic therapy. Expert Review of Molecular Diagnostics provides the forum for reporting the critical advances being made in this ever-expanding field, as well as the major challenges ahead in their clinical implementation. The journal delivers this information in concise, at-a-glance article formats: invaluable to a time-constrained community.